August 9, 2017 | Benchmark Litigation

Lisa Jose Fales Named a Leading Female Litigator by Benchmark Litigation

3 min

Washington, DC (August 9, 2017) – Venable LLP is pleased to announce that Lisa Jose Fales, chair of the firm's Antitrust Practice and co-chair of the Regulatory Practice, has been ranked among the "Top 250 Women in Litigation" for 2017 by Benchmark Litigation. This year marks the second time Ms. Fales has been named to the list. The annual ranking, based on months of research and client surveys, recognizes the achievements of the most distinguished female litigators in the U.S. 

For over 25 years, Ms. Fales has concentrated her practice on antitrust litigation, government investigations, mergers and acquisitions, and strategic antitrust counseling.

Ms. Fales is a key member of the Venable team that recently secured major successes in two highly significant antitrust cases. In In Re: Nexium Antitrust Litigation, following a complex six-week trial, a jury found for Venable client Ranbaxy, a leading multinational generic pharmaceutical company. This is the first and only "reverse payment" case to be tried to verdict since the U.S. Supreme Court's 2013 Actavis decision, holding that patent litigation settlements are subject to the rule of reason test under federal antitrust law. The case centered on Ranbaxy's patent litigation settlement with brand company AstraZeneca for the heartburn medicine Nexium. In November 2016, the First Circuit affirmed the Federal District Court’s denial of the plaintiffs' motions for a new trial.

Ms. Fales was also a leading member of the Venable team that delivered yet another highly successful outcome just last month for Ranbaxy, in only the second "reverse payment" case to go to trial since Actavis (the first being Nexium). On July 6, 2017, in In Re: Modafinil Litigation, after four intensive weeks of trial, closing arguments, and the jury being fully charged, Ranbaxy settled this litigation with the plaintiffs at trial, who alleged that Ranbaxy"s patent litigation settlement agreement with brand company Cephalon delayed generic entry of the sleep disorder drug Provigil.

Ms. Fales has been recognized by Global Competition Review for her antitrust litigation and government enforcement work, securing the firm's spot on Global Competition Review's list of the top 100 antitrust firms – the GCR 100 – and the Top DC Antitrust Practices. She was also named an "Outstanding Healthcare Antitrust Lawyer" by Nightingale's, and a Legal Elite winner by Washington SmartCEO magazine for achievements in antitrust law.


Venable LLP is an American Lawyer Global 100 law firm headquartered in Washington, DC that serves as primary counsel to a worldwide clientele of large and mid-sized organizations, nonprofits, and high-net-worth entrepreneurs and individuals. With more than 700 lawyers across the country, including California, Delaware, Maryland, New York, Virginia, and Washington, DC, the firm strategically advances its clients' business objectives in the U.S. and around the globe. Venable advises clients on a broad range of business and regulatory law, legislative affairs, complex litigation, and the full range of intellectual property disciplines. For more information, please visit